Argent BioPharma Limited (H5O0.F)
Every figure this model derived for H5O0.F, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-06-30.
The figures, and where each came from
This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.
| Figure | Value | XBRL tag | As at |
|---|---|---|---|
| capex | 140,123 | PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
2024-06-30 |
| cash | 702,870 | CashAndCashEquivalents |
2024-07-01 |
| current assets | 2,740,233 | CurrentAssets |
2024-07-01 |
| current liabilities | 12,176,097 | CurrentLiabilities |
2024-07-01 |
| equity | -5,152,448 | EquityAttributableToOwnersOfParent |
2024-07-01 |
| interest expense | 482,474 | FinanceCosts |
2024-06-30 |
| ocf | -14,662,491 | CashFlowsFromUsedInOperatingActivities |
2024-06-30 |
| revenue | 891,083 | RevenueFromContractsWithCustomers |
2024-06-30 |
The ratios
The figures themselves rather than their scores — what somebody looking up H5O0.F on one particular measure came for.
| Ratio | Value |
|---|---|
| cash operating margin | -1874.15 |
| current ratio | 0.23 |
| current ratio reported | 0.23 |
| fcf margin | -1661.19 |
| interest cover | -34.61 |
| operating margin | -1874.15 |
| owner earnings margin | -1661.19 |
| revenue growth | -73.7 |
| revenue growth per share | -73.7 |
| rule of 40 | -1947.85 |
| sbc pct revenue | 0.0 |
Everything else this filing tags
99 more elements from H5O0.F's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.
| Element | Newest | As of | Periods | Unit |
|---|---|---|---|---|
RetainedEarnings | -129,668,423 | 2024-07-01 | 3 | AUD |
IssuedCapital | 123,288,573 | 2024-07-01 | 3 | AUD |
IssueOfEquity | 19,097,773 | 2024-06-30 | 3 | AUD |
ComprehensiveIncome | -17,979,686 | 2024-06-30 | 3 | AUD |
ComprehensiveIncomeAttributableToOwnersOfParent | -17,917,541 | 2024-06-30 | 3 | AUD |
ProfitLoss | -17,548,433 | 2024-06-30 | 3 | AUD |
ProfitLossBeforeTax | -17,548,433 | 2024-06-30 | 3 | AUD |
ProfitLossAttributableToOwnersOfParent | -17,530,600 | 2024-06-30 | 3 | AUD |
ProfitLossFromOperatingActivities | -16,700,240 | 2024-06-30 | 3 | AUD |
Liabilities | 16,612,200 | 2024-07-01 | 3 | AUD |
ProceedsFromIssueOfSharesAndConversionOfOptionsClassifiedAsFinancingActivities | 15,941,552 | 2024-06-30 | 2 | AUD |
AdministrativeExpense | 15,556,230 | 2024-06-30 | 3 | AUD |
CashFlowsFromUsedInFinancingActivities | 15,266,321 | 2024-06-30 | 3 | AUD |
AdjustmentsForIncreaseDecreaseInTradeAccountPayable | -13,794,361 | 2023-06-30 | 2 | AUD |
PaymentsToSuppliersAndEmployeesClassifiedAsOperatingActivities | 13,522,196 | 2024-06-30 | 2 | AUD |
Assets | 10,787,380 | 2024-07-01 | 3 | AUD |
CurrentFinancialLiabilitiesAtFairValueThroughProfitOrLoss | 8,679,515 | 2024-07-01 | 3 | AUD |
NoncurrentAssets | 8,047,147 | 2024-07-01 | 3 | AUD |
NetAssetsLiabilities | -5,824,820 | 2024-07-01 | 3 | AUD |
Equity | -5,824,820 | 2024-07-01 | 4 | AUD |
PropertyPlantAndEquipment | 5,661,603 | 2024-07-01 | 3 | AUD |
ImpairmentExpense | 4,532,940 | 2023-06-30 | 2 | AUD |
NoncurrentLiabilities | 4,436,103 | 2024-07-01 | 3 | AUD |
NonCurrentDeferredRevenue | 4,277,865 | 2023-07-01 | 2 | AUD |
AdjustmentsForDecreaseIncreaseInTradeAccountReceivable | 3,959,182 | 2023-06-30 | 2 | AUD |
OtherOperatingExpenses | 3,642,897 | 2023-06-30 | 2 | AUD |
NoncurrentGovernmentGrants | 3,598,439 | 2024-07-01 | 2 | AUD |
ProceedsFromIssuingShares | 3,086,803 | 2023-06-30 | 2 | AUD |
TradeAndOtherCurrentPayables | 2,719,163 | 2024-07-01 | 3 | AUD |
PaymentsForResearchExpensesClassifiedAsOperatingActivities | 2,541,431 | 2024-06-30 | 2 | AUD |
IncreaseDecreaseThroughConversionOfConvertibleInstruments | 2,490,701 | 2022-06-30 | 1 | AUD |
ResearchAndDevelopmentExpense | 2,321,368 | 2024-06-30 | 2 | AUD |
AdjustmentsForIncreaseDecreaseInOtherOperatingPayables | -2,262,030 | 2023-06-30 | 2 | AUD |
ReceiptsFromCustomersClassifiedAsOperatingActivities | 1,398,193 | 2024-06-30 | 2 | AUD |
ImpairmentLossImpairmentGainAndReversalOfImpairmentLossDeterminedInAccordanceWithIFRS9 | -1,341,465 | 2024-06-30 | 2 | AUD |
InvestmentAccountedForUsingEquityMethod | 1,326,871 | 2024-07-01 | 2 | AUD |
EquityIssuedToExtinguishFinancialLiabilities | 1,317,500 | 2023-06-30 | 1 | AUD |
ReserveOfSharebasedPayments | 1,298,937 | 2024-07-01 | 3 | AUD |
AcquisitionOfZamSoftwareLtd | 1,231,245 | 2023-06-30 | 1 | AUD |
IncreaseDecreaseThroughAcquisitionOfSubsidiary | 1,231,245 | 2023-06-30 | 1 | AUD |
OperatingExpense | 1,095,767 | 2024-06-30 | 2 | AUD |
RightofuseAssets | 1,058,673 | 2024-07-01 | 3 | AUD |
Inventories | 875,120 | 2024-07-01 | 3 | AUD |
NoncurrentLeaseLiabilities | 820,911 | 2024-07-01 | 3 | AUD |
GovernmentGrantReceivedRelatingToPlanTandEquipmentClassifiedAsInvestingActivities | 796,066 | 2023-06-30 | 2 | AUD |
OtherIncome | 727,963 | 2024-06-30 | 3 | AUD |
CostOfSales | 687,386 | 2024-06-30 | 3 | AUD |
CurrentPrepayments | 685,713 | 2024-07-01 | 3 | AUD |
NoncontrollingInterests | -672,372 | 2024-07-01 | 3 | AUD |
CurrentDeferredRevenue | 658,133 | 2023-07-01 | 2 | AUD |
CurrentGovernmentGrants | 553,606 | 2024-07-01 | 2 | AUD |
OtherOperatingIncome | 528,213 | 2023-06-30 | 2 | AUD |
IssueOfConvertibleInstruments | 500,000 | 2024-06-30 | 1 | AUD |
TradeAndOtherCurrentReceivables | 476,530 | 2024-07-01 | 3 | AUD |
IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges | 463,707 | 2024-06-30 | 3 | AUD |
TransactionCostsOnIssueOfSharesClassifiedAsFinancingActivities | 436,552 | 2024-06-30 | 3 | AUD |
GainsLossesOnExchangeDifferencesOnTranslationNetOfTax | -431,253 | 2024-06-30 | 3 | AUD |
OtherComprehensiveIncome | -431,253 | 2024-06-30 | 3 | AUD |
OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax | -431,253 | 2024-06-30 | 2 | AUD |
OtherExpenseByFunction | 423,964 | 2024-06-30 | 2 | AUD |
DerecognitionOfPanaxPharmaSro | 400,932 | 2024-06-30 | 1 | AUD |
ResearchAndDevelopmentRebate | -371,215 | 2023-06-30 | 2 | AUD |
InterestPaidClassifiedAsOperatingActivities | 257,403 | 2023-06-30 | 2 | AUD |
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | 238,679 | 2024-06-30 | 3 | AUD |
CurrentLeaseLiabilities | 223,813 | 2024-07-01 | 3 | AUD |
GrossProfit | 203,697 | 2024-06-30 | 3 | AUD |
IncreaseDecreaseThroughSharebasedPaymentTransactions | 187,996 | 2024-06-30 | 3 | AUD |
CashFlowsFromUsedInInvestingActivities | -140,123 | 2024-06-30 | 3 | AUD |
FairValueMovementOnFinancialInstruments | 131,409 | 2023-06-30 | 2 | AUD |
AcquisitionOfCzechRussia | -109,378 | 2022-06-30 | 1 | AUD |
ReserveOfExchangeDifferencesOnTranslation | -71,535 | 2024-07-01 | 3 | AUD |
ComprehensiveIncomeAttributableToNoncontrollingInterests | -62,145 | 2024-06-30 | 3 | AUD |
MiscellaneousOtherOperatingIncome | 56,316 | 2024-06-30 | 2 | AUD |
OtherLongtermProvisions | 21,009 | 2023-07-01 | 2 | AUD |
ProfitLossAttributableToNoncontrollingInterests | -17,833 | 2024-06-30 | 3 | AUD |
NoncurrentProvisions | 16,753 | 2024-07-01 | 2 | AUD |
GovernmentGrantsAndTaxPaidClassifiedAsOperatingActivities | -6,000 | 2024-06-30 | 2 | AUD |
FinanceCostsPaidClassifiedAsOperatingActivities | 3,057 | 2024-06-30 | 2 | AUD |
GovernmentGrantsAndTaxPaid | -2,018 | 2023-06-30 | 2 | AUD |
FinanceIncome | 1,929 | 2024-06-30 | 3 | AUD |
EffectOfExchangeRateChangesOnCashAndCashEquivalents | -658 | 2024-06-30 | 3 | AUD |
InterestReceivedClassifiedAsOperatingActivities | 240 | 2023-06-30 | 2 | AUD |
BasicAndDilutedLossForTheYearAttributableToOrdinaryEquityHoldersOfTheParent | -1 | 2023-06-30 | 2 | AUD/shares |
BasicAndDilutedEarningsLossPerShare | -0 | 2024-06-30 | 2 | AUD/shares |
IncomeTaxExpenseContinuingOperations | 0 | 2024-06-30 | 3 | AUD |
IntangibleAssetsAndGoodwill | 0 | 2023-07-01 | 2 | AUD |
NoncurrentFinancialAssets | 0 | 2023-07-01 | 2 | AUD |
ConsolidationReserve | 0 | 2024-07-01 | 3 | AUD |
ExerciseOfPerformanceRights | 0 | 2023-06-30 | 2 | AUD |
IncreaseDecreaseThroughExerciseOfOptions | 0 | 2023-06-30 | 2 | AUD |
CashAcquiredThroughAssetsAcquisitionClassifiedAsInvestingActivities | 0 | 2023-06-30 | 2 | AUD |
OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities | 0 | 2023-06-30 | 2 | AUD |
ProceedsFromBorrowingsClassifiedAsFinancingActivities | 0 | 2024-06-30 | 3 | AUD |
RepaymentsOfBorrowingsClassifiedAsFinancingActivities | 0 | 2024-06-30 | 3 | AUD |
IncreaseDecreaseInFairValueMeasurementLiabilities | 0 | 2024-06-30 | 2 | AUD |
TransferOfExpiredShareBasedPayments | 0 | 2024-06-30 | 1 | AUD |
ResearchAndDevelopmentRebateClassifiedAsOperatingActivities | 0 | 2024-06-30 | 2 | AUD |
FinanceIncomeReceivedClassifiedAsOperatingActivities | 0 | 2024-06-30 | 2 | AUD |
ProceedsFromGovernmentGrantsClassifiedAsInvestingActivities | 0 | 2024-06-30 | 2 | AUD |
What to be careful about
What this model itself distrusts about H5O0.F's figures. Written by the derivation as it ran, not added afterwards.
- WITHHELD: net margin -- net margin came out at -1,969% against a scale that tops out near 1,500%, which is arithmetic on a revenue figure of 891,083 rather than a margin. The figure is absent rather than corrected: there is no right value to put here.
- newest fact in the filing is 2024-07-01 (2y old); this company's data is not usable and the scores below should be ignored
- revenue is annual, not TTM
- operating income is annual, not TTM
- revenue period ends 2024-06-30 (841 days ago) - the tag chain found nothing recent, so treat this row as unscored
- no current stock compensation tagged; treated as zero, so owner earnings are overstated
- no market cap; set `market_cap` in overrides.yaml
- reports in AUD while its share price is quoted in EUR, and no exchange rate could be used (no rate for EUR to AUD that is less than 30 days old, and this is not a refresh). Every multiple would pair one currency with another, so none of them is a ratio — set `market_cap` in overrides.yaml in AUD to score it
- no usable diluted share count, so growth is measured on total revenue rather than per share; a company issuing shares to fund that growth reads better than it is
- analyst estimate not used: no trailing EPS to measure the growth from
- quality rests on 4 of 5 inputs; not tagged: roic
- valuation DROPPED from the total: only 0 of 2 inputs could be computed (ev sales, ev owner earnings not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
- durability DROPPED from the total: only 2 of 4 inputs could be computed (worst year, contracted coverage not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
- growth rests on 3 of 4 inputs; not tagged: sustained growth
- 2 of 5 dimensions could not be measured (valuation, durability -- 35% of the model), so this row is not comparable with the others; its total rests on what was left